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our view, the effect of income does not only reflect money they lost.
CONCLUSIONS: An assumed income reduction clearly influenced utility scores,
however compensation for lost income fail to improve utility scores. Our results
suggest that income does not significantly influence utility scores and that the
impact of double counting is negligible.
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OBJECTIVES: To review published cost-utility analyses (CUA) targeted towards
populations in Asia.METHODS:We examined data from the Tufts Medical Center
Cost-Effectiveness Analysis Registry (www.cearegisty.org), which contains de-
tailed information on more than 2,900 English-language CUAs in peer-reviewed
journals. We focused on articles pertaining to Asian countries, summarized study
features for articles published from 2000-2010, and compared those with CUAs in
all other countries. RESULTS: Of 2,367 CUAs published during 2000-2010, 87 (3.7%)
pertained to Asian countries: Japan (n34), Taiwan (n18), China (n9), Thailand
(n7), Hong Kong (n5), Singapore (n5), South Korea (n5), India (n4), and
Bangladesh (n1). The CUAs contained 243 standardized incremental cost-effec-
tiveness ratios (ICERs, expressed as $US2010 per QALY) and 357 utility weights. The
most common type of intervention was pharmaceuticals (52.9%), followed by
screening (21.8%), diagnostics (11.5%), and surgery (11.5%). 79 CUAs (90.8%) men-
tioned a cost-effectiveness threshold; of these, 60 said “good value for money”
reflected a threshold below $50,000/QALY. The median reported ICER was $11,000/
QALY, vs. $21,000/QALY for non-Asian studies. 75.7% of the reported ICERs were
either dominant (less expensive and more effective) or below $50,000/QALY, com-
pared to 63.9% in non-Asian CUAs (p0.001). 13.6% of ICERs were either dominated
(more expensive and less effective) or greater than $100,000/QALY, compared to
22.4% in non-Asian CUAs (p0.001). CUAs targeted towards Asian populations gen-
erally adhered to good methodological practices, though the average quality score
wasmodestly lower than the overall mean (4.08 vs. 4.43, p0.001) and significantly
more studies did not report funding sources (40.2% vs. 22.2%, p0.001), compared
with non-Asian CUAs. CONCLUSIONS: The number of CUAs in Asia has grown
steadily with over half focused on pharmaceuticals. Compared to CUAs in all other
countries, significantly more studies in Asia suggest efficient health interventions.
These CUAs generally follow good methodological practices though reporting of
funding sources could improve.
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OBJECTIVES: Indirect cost is an important component in cost-of-illness assess-
ment. This study explored the factors involved in the variation of reported indirect
cost and investigated the feasibility of transferring indirect costs across settings.
METHODS: A systematic literature review was conducted to identify studies esti-
mating indirect costs for four selected chronic diseases, namely, asthma (AS), dia-
betes (DI), rheumatoid arthritis (RA), and schizophrenia (SC). Multiple linear regres-
sion was run to identify the factors that potentially explain the variation of
reported indirect costs. Parametric (fixed and random-effect model) and non-para-
metric (bootstrappingmethod)meta-analyses were applied to local gross domestic
product (GDP) per capita adjusted indirect costs for each disease. RESULTS: Sys-
tematic literature review identified 77 articles that reported indirect costs of AS
(18), DI (20), RA (25), and SC (14) for literature synthesis. Substantial inter- and
intra-disease variations among the indirect cost studies were observed, regarding
the geographic distribution, methodology and magnitude of cost estimation. Re-
gression analysis showed disease categories and local GDP per capita significantly
(P0.001) contributed to the variance of indirect cost. The range of intra-disease
variation in indirect cost was subsatntially reduced after adjusting by and express-
ing as of local GDP/capita. GDP adjusted indirect cost in terms of percentage of local
GDP/capita of AS was the lowest and that of SC was the highest. Bootstrapping
estimation was relatively conservative with slightly larger confidence intervals
than the parametric method with themean (95%CI) of 2.12% (1.4089, 2.9332) on AS,
10.65% (7.215, 14.7438) on DI, 21.98% (17.4360, 27.0631) on RA, and 79.19% (52.4243,
117.833) on SC. CONCLUSIONS: It would be convenient and feasible to construct a
universal reference range of indirect cost for a specific disease based on existing
data and presented as a percentage of local GDP to assist local decision making in
jurisdictions where indirect cost data are not available.
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OBJECTIVES: Singapore has a modified universal health care system in which sub-
sidy rates are pegged to household incomes and other socioeconomic attributes.
Out-of-pocket charges vary considerably for each service and level of subsidy.
Hence, costing issue needs to be carefully considered in cost utility study in the
context of Singapore, depending on the perspective from which the analyses are
performed. This research was to explore the costing consideration for different
possible scenarios through an illustrative cost utility analysis. METHODS: Using
the incremental cost and QALY gained data presented in a published cost utility
analysis of a treatment for breast cancer in the context of Singapore, hypothetical
scenarioswere assumed for different levels of subsidy (50%, 75% and 100%) covered
by the public health care provider that a patient might receive at a government
restructure hospital. Assuming the QALY gained remains the same, incremental
cost per QALY gained (ICER) was computed for each scenario from the perspective
of the public health care provider. RESULTS: For a fully subsidy scenario (100%), the
total incremental costwas S$62,770. In the case of subsidy rates at 50%and 75%, the
incremental total costs were S$31,385 and S$47,077, respectively. For the same
expected gained of 1.70 QALYs, the resulting ICERs were S$18,462, S$27,692 and
S$36,924 for scenarios of 50%, 75% and 100% subsidy rates, respectively.
CONCLUSIONS: Due to the possible different subsidy rates for most of the costing
items in a cost utility analysis, careful considerationwith explicit cost computation
from a clearly defined perspective is recommended. Aweighted total cost based on
the distribution of possible subsidy levels and relevant sensitivity analyses should
be considered in a pharmacoeconomic study from the perspective of the public
health care provider of Singapore.
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OBJECTIVES: Both Korea and Australia have stringent pharmaco-economic (PE)
guidelines outlining the data requirements for cost effectiveness analysis (CEA).
The requirements for regulatory approval in both countries are clear and mainly
rely on multinational clinical trials with the addition of relative small bridging
studies in Korea. It seems, however, to be different for reimbursement submission
where CEAs are presented.The purpose of this study is to uncover the data require-
ments for CEA from an industry perspective.METHODS: Firstly a literature search
was performed to find any relevant publications. Moreover website of decision
maker’s were searched for past reimbursement decisions. Finally a qualitative
comparison was made of the PE guidelines for Korea and Australia. RESULTS: The
literature search revealed very little published literature on CEAs as part of drug
reimbursement submissions inKorea andAustralia. Decisionmakers in both coun-
tries publish reimbursement decisions on their respective website. However the
information disclosed rarely reveals what input data was used for CEAs. The PE
guidelines for the respective countries showed remarkable similar data require-
ments. The main difference is surrounding local resource data. In Korea this usu-
ally retrieved through information gathering exercises like cost and utilisation
studies. It is quite different in Australia where most information is available either
through a government website or as IMS data. CONCLUSIONS: Both Korea and
Australia has specific requirements for CEAs however the local data needed for
each country differs significantly. Acquiring cost and utilisation data in Australia
seems straight forward in most cases, whereas the situation is different in Korea.
Not only does it have an impact on time to market for new innovative pharmaceu-
ticals but it also increases the uncertainty surrounding the result of the CEA mak-
ing it more difficult for decision makers to make a decision.
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OBJECTIVES:The PROLabels database (www.mapi-prolabels.org) is a unique online
tool collecting information on the medical and biological products for which the
Food and Drug Administration (FDA) and the European Medicines Agency (EMA)
have granted a Patient-Reported Outcome (PRO) labeling claim. The purpose of this
abstract is to present an overview of the database six years after its implementa-
tion in April 2006. METHODS: To create the database, data were retrieved on the
EMA website, from the European Public Assessment Reports for all the drugs ap-
proved through a centralized procedure since 1995. Evidence of a PRO endpointwas
pulled for each product from the Summary of Product Characteristics and, when
necessary, additional information was gathered from the scientific discussions.
From the FDAwebsite, datawere collected from the approved labels and additional
information was retrieved in the Medical Reviews. The database now contains all
drugs approved or revised by the FDA since 1995, including Biological Approvals
(BLAs). For the purpose of this review, all approvals between 1995 and 2011 were
reviewed individually for each agency. RESULTS: As of December 31, 2011, the
database contains 486 records of which 342 products were approved by the FDA
(22.6% of all FDA approvals). Therewere 144 productswith a PRO claim approved by
the EMA (24.2% of all EMA approvals). Nervous system diseases is the therapeutic
area for which the highest number of products is approved with a PRO claim
(n153), followed by the immune system diseases (n105). Signs and symptoms
are the most frequently measured PROs while health-related quality-of-life repre-
sents only 16.9% of all drugs approved with a PRO claim. CONCLUSIONS: The
PROLabels database provides easy access to information regarding PRO claims in
approved labels for both FDA and EMA in one location and information about PRO
claims trends in the USA and Europe.
PRM11
EVIDENCE FOR VALIDITY OF A NATIONAL PATIENT-REPORTED SURVEY IN
JAPAN: THE JAPAN NATIONAL HEALTH AND WELLNESS SURVEY
Dibonaventura MD1, Fukuda T2, Stankus A3
A646 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 6 0 2 – A 6 8 1
